Eupraxia Pharmaceuticals Reports Positive 36-Week Data from Highest Dose Cohort in Eosinophilic Esophagitis RESOLVE Trial

Key Takeaways

• Cohort 9 patients demonstrated robust improvements in both tissue health and symptom response at 36 weeks compared to baseline
• Highest dose group showed superior tissue health response compared to all other dose cohorts in the RESOLVE trial
• First release of long-term 36-week data provides crucial efficacy insights for this rare inflammatory esophageal condition

---

Eupraxia Pharmaceuticals announced positive nine-month results from the highest dose cohort in its ongoing Phase 1b/2a RESOLVE trial for eosinophilic esophagitis (EoE), marking the first release of 36-week tissue health and symptom data from Cohort 9.

Strong Efficacy Signals in Highest Dose Group

At 36 weeks, the three patients in Cohort 9 demonstrated robust improvements in both tissue health and symptom response compared to their baseline measurements. Notably, this highest dose cohort achieved superior tissue health outcomes compared to all other dose groups evaluated in the RESOLVE trial to date.

The data represents a significant milestone for Eupraxia’s experimental treatment approach to eosinophilic esophagitis, a chronic inflammatory condition affecting the esophagus that can cause difficulty swallowing, food impaction, and reduced quality of life.

IntelligenceRegulatory Impact▾

EMA and MHRA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Clinical Implications and Market Context

Eosinophilic esophagitis affects approximately 150,000 people in the United States, with limited treatment options currently available. The condition is characterized by elevated eosinophil counts in esophageal tissue and can lead to esophageal remodeling if left untreated.

The positive tissue health data is particularly encouraging, as histological improvement represents a key regulatory endpoint for EoE treatments. Current therapies include proton pump inhibitors, topical corticosteroids, and dietary elimination, but many patients continue to experience symptoms and tissue inflammation.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Next Steps in Development

The RESOLVE trial continues to evaluate multiple dose cohorts as part of its dose-escalation design. The strong performance of Cohort 9 may inform optimal dosing strategies for potential Phase 2 studies and provide valuable insights into the therapeutic window for Eupraxia’s investigational treatment.

The company has not yet disclosed specific timelines for completing the current trial phase or advancing to larger efficacy studies. However, the positive tissue health and symptom data from the highest dose group represents an important proof-of-concept for the therapeutic approach.

---

Frequently Asked Questions

What is eosinophilic esophagitis and how common is it?

Eosinophilic esophagitis (EoE) is a chronic inflammatory condition affecting the esophagus, characterized by elevated eosinophil counts in tissue. It affects approximately 150,000 people in the US and can cause difficulty swallowing and food impaction.

When will Eupraxia’s EoE treatment be available to patients?

The treatment is still in Phase 1b/2a trials. The company has not disclosed timelines for completing current studies or advancing to Phase 2, so commercial availability is likely several years away pending successful trial completion and regulatory approval.

How does this compare to existing eosinophilic esophagitis treatments?

Current EoE treatments include proton pump inhibitors, topical corticosteroids, and dietary changes, but many patients continue experiencing symptoms. The positive tissue health data suggests Eupraxia’s approach may offer improved efficacy, though direct comparisons await larger controlled studies.

Related coverage

• Arrowhead Pharmaceuticals Presents Positive Cardiometabolic Data at European A Meeting
• X4 Pharmaceuticals Secures Positive EMA CHMP Opinion for Mavorixafor in WHIM Syndrome
• Quoin Pharmaceuticals Aims for First Peeling Skin Syndrome Trial with FDA IND Submission